Skip to content

Metabolome Analysis in Patients With Rheumatoid Arthritis

Metabolome Analysis in Patients With Rheumatoid Arthritis

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02960958
Enrollment
200
Registered
2016-11-10
Start date
2016-11-20
Completion date
2019-10-31
Last updated
2018-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

RheumatoId Arthritis

Keywords

Rheumatoid arthritis, Metabolomics, urine

Brief summary

The aim of this study is to investigate discriminant metabolites in urine from patients with rheumatoid arthritis (RA) from healthy individuals. Then we determine if the patient's metabolic fingerprint could predict the development or flare-up of RA.

Detailed description

Compare metabolites between RA patients and healthy individuals. 1. Collection urine sample 2. Assessing urine metabolites by 1H NMR spectroscopy 3. Analyzing the relationships between metabolites and clinical variables

Interventions

None listed

Sponsors

The Catholic University of Korea
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* All patients with rheumatoid arthritis meet 2010 American College of Rheumatology/European League against Rheumatism classification criteria.

Exclusion criteria

* Comorbid with other autoimmune diseases * Confirmed with amyloidosis * Chronic kidney disease (estimated GFR \< 60 ml/min/1.73m2) * Chronic liver disease * Thyroid disease * Pregnancy * Solid tumor/hematologic malignancy within 5 years

Design outcomes

Primary

MeasureTime frameDescription
Metabolic fingerprint of rheumatoid arthritis1 yearsMetabolomic analyses of urine from patients with rheumatoid arthritis, healthy controls and other autoimmune disease

Secondary

MeasureTime frameDescription
Correlations between specific metabolites and disease activity/severity of RA1 yearIdentified metabolites and their clinical significances

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026